Research programme: T-cell therapies - CRISPR Therapeutics

Drug Profile

Research programme: T-cell therapies - CRISPR Therapeutics

Latest Information Update: 28 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CRISPR Therapeutics
  • Developer CRISPR Therapeutics; Massachusetts General Hospital
  • Class Antineoplastics; T lymphocyte cell therapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Research Haematological malignancies; Solid tumours

Most Recent Events

  • 22 Aug 2017 CRISPR Therapeutics enters into a two-year research collaboration and license option agreement with Massachusetts General Hospital to develop novel T-cell therapies for Cancer
  • 22 Aug 2017 Early research in Haematological malignancies in USA (Parenteral)
  • 22 Aug 2017 Early research in Solid tumours in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top